trial · primary record
Surovatamig
Chronic Lymphocytic Leukaemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 408 |
| Primary completion | 2030-05-20 |
| Primary endpoint | Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest |
| Registry ID | NCT06564038 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:30.478Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06564038
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Surovatamig · compound